# Med-X BCI-2035 Perspective **Entity class:** Publication **Domain:** Brain-Computer Interfaces / Translational Priority-Setting **Doc Type:** Publication Node **Maturity:** Developing **Collection:** [[collections/Neurotech|Neurotech]] **Primary Sources:** [[wiki/Med-X|Med-X]] article list (23 October 2026) ## Definition **"Identifying brain-computer interface translational priorities with an outlook on the field in 2035" is a Perspective by Ning Jiang, Jiayuan He and Xiaohong Sui, published in [[wiki/Med-X|Med-X]] on 9 October 2026.** It scores twelve neurological conditions with an urgency–importance–impact framework built on disability-adjusted life years (DALYs) and identifies **Alzheimer's disease, stroke, depression and anxiety** as the top strategic targets for brain-computer interfaces. ## Reading A DALY-weighted ranking is a reimbursement argument written in epidemiological units: it tells sponsors which indications can carry the cost of an implant, a decoder and a care pathway through the next decade. The four named conditions match the indications where 2026 programs already concentrate. Stroke leads registered Chinese BCI trials (65.0% of studies in a July 2026 landscape analysis), and [[wiki/Cortec|CorTec]] received a second FDA Breakthrough designation for stroke on 30 August 2026. Depression is the indication of [[wiki/Motif Neurotech|Motif Neurotech]]'s April 2026 IDE and of the wearable vagus-nerve work reviewed in the same journal. Alzheimer's disease is the largest DALY burden on the list and the least served by current implant programs, which makes it the open position. ## Supporting record in Med-X The journal's own archive supplies the adjacent evidence for each carrier: - **Alzheimer's disease:** a meta-analysis of 79 randomized controlled trials comparing non-invasive brain stimulation and physical exercise in mild cognitive impairment and Alzheimer's disease, finding non-invasive stimulation the more promising for delaying decline (17 January 2025). - **Depression and anxiety:** a review of [[wiki/Vagus Nerve Stimulation|wearable vagus nerve stimulation]] for treatment-resistant depression with AI-driven closed-loop personalization (25 August 2026), and a review of intelligent sensing devices for personalized mental health (2 April 2025). - **Motor and stroke:** a review of motor-cortex research through the experiment–analysis–model flywheel (24 July 2025). - **Closed-loop hardware:** reviews of adhesive bioelectronics for closed-loop therapy (1 May 2025), hydrogels in wearable neural interfaces (9 December 2024) and passive wireless inductor-capacitor sensors (21 August 2025). ## Open Questions - The full scoring table for all twelve conditions, the weights, and the authors' affiliations; the article page redirected automated retrieval on 23 October 2026. - Whether the 2035 outlook names device classes, channel counts or regulatory milestones. ## Research Inferences These entries translate the forward-looking register in [[research/Research Inferences|Research Inferences]] into ordinary wiki prose. The tier labels apply to the inference, not automatically to every factual anchor inside it. Proposed IDs above INF-0500 and tier recommendations come from the 2026-10-23 cycle: [[research/Research Inferences Integration Report - 2026-10-23|Research Inferences Integration Report — 2026-10-23]] · [[research/Research Inferences Integration Audit - 2026-10-23|Research Inferences Integration Audit — 2026-10-23]]. - **INF-0491 — Analytic.** Every capability in this corpus enters the world through a medical indication because that is the funded, permitted, and reimbursable route. The indication is the carrier wave, and the capability is the signal. - **INF-0490 — Strongly indicated.** The consequential capabilities arise from composition rather than from any single advance: editing plus sensing gives real-time repair, decoding plus modeling gives cognitive mediation, preservation plus emulation gives deferred continuity. Composition is where the forward argument lives. - **INF-0071 — Analytic.** Parkinson's affects over ten million people globally with about one million in the United States, which gives closed-loop neural implants an addressable population large enough to industrialize manufacturing. Industrial volume in medical implants is what makes consumer volume physically possible later. - **INF-0501 (proposed) — Analytic.** A DALY ranking is a reimbursement argument written in epidemiological units, and the four named indications are the carriers most likely to fund the next decade of BCI capability. ## Relationships - **published_in:** [[wiki/Med-X|Med-X]] (Shanghai Jiao Tong University with Springer Nature), Volume 4, 9 October 2026. - **ranks_indications_for:** [[wiki/Brain-Computer Interfaces|Brain-Computer Interfaces]]. - **indication_match:** [[wiki/Cortec|CorTec]] (stroke) · [[wiki/Motif Neurotech|Motif Neurotech]] (depression) · [[wiki/Treatment-Resistant Depression|Treatment-Resistant Depression]] · [[wiki/Vagus Nerve Stimulation|Vagus Nerve Stimulation]]. - **context:** [[wiki/China BCI Industry Implementation Opinions|China BCI Industry Implementation Opinions]] (national targets for clinical deployment by 2027). - **cluster_home:** [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] · [[wiki/Neural Interfaces and Continuity Architecture|Neural Interfaces and Continuity Architecture]] · [[collections/Neurotech|Neurotech]]. ## Sources - [Identifying brain-computer interface translational priorities with an outlook on the field in 2035 — Med-X, 9 October 2026](https://link.springer.com/article/10.1007/s44258-026-00095-5) - [Med-X articles list — Springer Nature Link](https://link.springer.com/journal/44258/articles) - [Clinical Translation of Brain-Computer Interface in China — arXiv 2607.07185, July 2026](https://arxiv.org/pdf/2607.07185) As of 23 October 2026.